You are here: Industry Insights > Prostate Cancer

News List

Canada clinical trial on personalised medicine for prostate cancer europeanpharmaceuticalreview
November 29, 2018
A clinical trial could be the world’s first to look at personalised medicine in prostate cancer, with patients taking a therapy based on their DNA markers…
Researchers to trial prostate cancer saliva test pharmatimes
July 10, 2018
An international team of researchers, led by scientists at The Institute of Cancer Research, London, are planning to trial a novel saliva-based DNA test designed to predict men at risk of developing prostate cancer.
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer pharmatimes
July 06, 2018
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy (ADT) and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
NICE says Tookad too expensive for prostate cancer pharmatimes
July 04, 2018
The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer.
Keytruda offers significant hope in subset of prostate cancer pharmafile
June 07, 2018
Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at ASCO, a team from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust were able to use MSD’s Keyt
Trial first to show immunotherapy benefit in prostate cancer pharmatimes
June 06, 2018
An international trial led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust has shown that immunotherapy can benefit men with prostate cancer.
Look out, J&J. Sun Pharma's Yonsa nod in prostate cancer puts Zytiga on notice fiercepharma
May 28, 2018
Early this year, Johnson & Johnson prostate cancer blockbuster Zytiga took an unexpected hit when a U.S. court stripped away a key patent, opening the prospect of generic launches later this year—a prospect J&J is working hard to avoid
Sun Pharma drug combo scoresFDA approval in advanced castration-resistant prostate cancer pharmafile
May 25, 2018
Sun Pharma is celebrating with the announcement that its CYP17 inhibitor Yonsa (abiraterone acetate) has been awarded FDA approval in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult
Attacking treatment-resistant prostate cancer by blocking its stress response fiercebiotech
May 03, 2018
Prostate cancer cells rely on protein synthesis to fuel their growth, but there can be too much of a good thing: Prostate tumors that are flooded with protein will actually die.
Researchers to investigate screening for prostate cancer using MRI europeanpharmaceuticalreview
April 09, 2018
A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately…

Previous page 1 2 3 4 5 6 7 8 9 10 Next page